What are ADC's

Our services

ADC Review
is made possible by:

NCT00284804 (Clinical Trial / MDX-060)

Study Title
A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin’s Disease (NCT00284804)

Trial Description
This study is designed to determine the objective response rate in patients with relapsed or refractory Hodgkin’s disease treated with MDX-060, also known as iratumumab, in combination with gemcitabine or gemcitabine alone.

This trial is sponsored by Bristol-Myers Squibb. [1]

Study Data

  • Condition: Hodgkin’s Disease
  • Interventions:
    • Drugs used in this trial
      • MDX-060 (Iratumumab; Medarex/Bristol-Myers Squibb)
  • Phase: II
  • Enrollment: 74
  • Start: November 2005
  • Study Completion: October 2009
  • Last verified: November 2012

Study Schematic

(Coming soon)

Click here to Return to Drug map

Last Editorial review: July 17, 2015
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...

Skip to toolbar